Ten companies boasted gains on Tuesday, bucking a broader market pessimism, thanks to a flurry of company-specific catalysts that boosted buying appetite. Of the firms in the list, four notably notched new record highs.
In contrast, Wall Street’s main indices all finished in the red, led by the Dow Jones, down 0.80 percent, followed by the S&P 500, declining 0.19 percent, and the Nasdaq, dipping 0.10 percent.
In this article, we spotlight the 10 top performers on Tuesday and break down the reasons behind their gains.
To come up with the list, we focused exclusively on stocks with more than $2 billion in market capitalization and 5 million shares in trading volume.
The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels
10. Venture Global Inc. (NYSE:VG)
Venture Global rallied for a second day on Tuesday, clocking 6.78 percent gains to close at $7.88 apiece as investors resumed buying positions amid the stronger demand for energy during the winter season.
Traders typically believe a seasonal strength in the energy sector during the winter season as households and businesses ramp up their power consumption for their heating needs. In turn, this results in stronger demand for natural gas exports.
Tuesday’s rally reflected strong confidence for Venture Global Inc. (NYSE:VG) in the first quarter of the year, despite lowering anew on Monday its adjusted EBITDA forecast for the fourth quarter and full-year 2025.
In a regulatory filing, Venture Global Inc. (NYSE:VG) said that it further lowered its adjusted EBITDA forecast to a range of $6.18 billion to $6.24 billion, versus $6.35 billion to $6.5 billion previously.
During the period, it also exported 128 cargos from its LNG facilities, selling as much as 478.3 trillion British thermal units (BTUs) at an implied average price of $5.15 per MMBtus.
Official results are expected to be released in the second week of February 2025.
9. Intel Corporation (NASDAQ:INTC)
Intel Corp. soared to a nearly two-year high on Tuesday, as investors took path from an investment firm’s bullish outlook for its stock.
At intra-day trading, the stock jumped to its highest price of $48.24 before trimming gains to finish the session just up by 7.33 percent at $47.29 apiece.
In a market report, KeyBanc issued an “overweight” recommendation on shares of Intel Corporation (NASDAQ:INTC) and Advanced Micro Devices Inc. on the back of stronger-than-expected data center demand and tighter memory supply in the semiconductor industry.
Having already sold out its server CPUs in 2026, Intel Corporation (NASDAQ:INTC) alone received a $60 price target from KeyBanc, marking a 27 percent upside potential from its latest closing price, due to a strong demand from hyperscalers which is already disrupting supply chains and pushing DRAM and NAND prices higher to as much as 10 to 15 percent.
Additionally, KeyBanc said that it also took into account the company’s improving manufacturing yields, noting that Intel’s 18A process is now more than 60 percent and good enough to ramp up Panther Lake.
After market close next Thursday, January 22, Intel Corporation (NASDAQ:INTC) is set to release the results of its earnings performance for the fourth quarter and full-year 2025. Investors will also closely watch out for the company’s business outlook for 2026.
8. Option Care Health Inc. (NASDAQ:OPCH)
Option Care extended gains for a second day on Tuesday, nearly hitting its 52-week high, as investors cheered higher preliminary net revenues for full-year 2025.
At intra-day trading, the stock jumped to as much as $35.47—just 6 cents shy of its 52-week high of $35.53. It trimmed gains at the end of the session to finish the day just up by 8.39 percent at $34.75 apiece.
In a statement, Option Care Health Inc. (NASDAQ:OPCH) said that it is gunning for net revenues between $5.645 billion and $5.655 billion for the said period, or the higher end of its earlier guidance range of $5.60 billion to $5.65 billion.
It also expects to report net income between $59.1 million and $62.4 million, as adjusted diluted earnings per share (EPS) of $1.72 to $1.76, versus its previous guidance of $1.68 to $1.72.
Adjusted EBITDA is targeted at $469 million to $473 million, marking a higher low-end of its previous $468 million to $473 million guidance range.
For the fourth quarter alone, net revenues are targeted at $1.46 billion to $1.47 billion, with net income of $59.1 million to $62.4 million.
Diluted EPS is at $0.37 to $0.39, while adjusted EBITDA is pegged at $123.7 million to $127.7 million.
Official results are scheduled to be released next month, alongside its full-year 2026 financial guidance.
7. ImmunityBio Inc. (NASDAQ:IBRX)
ImmunityBio extended its winning streak to an 8th straight day on Tuesday, jumping 8.88 percent to finish at $2.82 apiece as investors cheered positive results from its clinical trial of Anktiva in combination with a checkpoint inhibitor on patients with non-small cell lung cancer (NSCLC).
In an updated report, ImmunityBio Inc. (NASDAQ:IBRX) said that Anktiva plus CPI showed statistically significant immune restoration and a consistent association between lymphocyte recovery and improved survival across 151 patients enrolled in two studies.
Checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo) have transformed the treatment landscape for lung cancer. However, ImmunityBio Inc. (NASDAQ:IBRX) said that clinical benefit is often transient, and effective treatment options remain limited once patients progress following standard-of-care chemo-radiation and checkpoint inhibition.
ImmunityBio Inc. (NASDAQ:IBRX) said that detailed results from both studies are being prepared for peer-review publication and future scientific presentations and serve as foundational safety and efficacy data demonstrating meaningful clinical benefit in patients with NSCLC who have failed all standards of care including checkpoint inhibitors.
6. T1 Energy Inc. (NYSE:TE)
T1 Energy soared to an over two-year high on Tuesday, as investors took heart from an analyst’s bullish outlook on its partnership with Nextracker Inc.
At intra-day trading, the stock jumped to a new high of $8.51 before paring gains to finish the session just up by 9.02 percent at $7.86 apiece.
This followed a market report from Zacks Research, saying that T1 Energy Inc.’s (NYSE:TE) multi-gigawatt solar module frame supply agreement with Nextracker Inc. last October would help accelerate the industry’s shift from imported aluminum frames toward US-made, specialty steel alternatives, supporting domestic demand for more durable solar technologies.
Under the agreement, T1 Energy Inc. (NYSE:TE) would use Nextracker’s patented steel module frame technology for its 5 GW solar manufacturing facility in Dallas, Texas.
In other news, T1 Energy Inc. (NYSE:TE) recently implemented a broader restructuring initiative in a bid to comply with US government laws and continue its qualification for the 2026 tax credits.
This followed the amendment of its certificate of incorporation to impose limits on its foreign ownership, repayment of existing debt to a Chinese investor, as well as the removal of the latter’s previous right to appoint a covered officer.
Signed into law last July, the OBBBA restricts companies with excessive foreign ownership from receiving 45X tax credits, particularly those tied to what the US identified as “prohibited foreign entities” such as those from China, North Korea, Russia, and Iran.
Additionally, tax credits received by the eligible companies are not allowed to be sold or transferred to PFEs.
5. Warby Parker Inc. (NYSE:WRBY)
Warby Parker bounced back by 9.44 percent on Tuesday to close at $29.09 apiece, as news of strong demand for artificial intelligence glasses spilled over to its stock.
At intra-day trading, Warby Parker Inc. (NYSE:WRBY) climbed to as much as $30, just $1 shy of its 52-week high of $31, following news that Meta Platforms and EssilorLuxottica are ramping up production for their AI-powered glasses by the end of the year to meet strong demand.
Optimism dribbled into Warby Parker Inc. (NYSE:WRB), which is also set to unveil its own AI glasses, in partnership with Google, sometime this year. The product would incorporate multimodal AI with prescription and non-prescription lenses.
Under its agreement with Google, the eyewear maker would design and develop the AI glasses, while Google would finance the product development for $75 million, alongside an optional investment in the former for another $75 million, subject to the achievement of certain milestones.
In other news, Warby Parker Inc. (NYSE:WRBY) earlier maintained a “buy” recommendation from investment firm TD Cowen, alongside an 8 percent upgrade for its price target on strong optimism for its AI glasses.
4. Roblox Corporation (NYSE:RBLX)
Roblox surged for a second day on Tuesday, jumping 10.53 percent to close at $84.80 apiece, as investors gobbled up shares ahead of the results of its earnings performance for full-year 2025.
In a statement, Roblox Corporation (NYSE:RBLX) said that it is scheduled to release its financial and operating highlights for the period after market close on February 5, 2026. It would hold a conference call on the same day to detail the results.
In its last earnings call, Roblox Corporation (NYSE:RBLX) said that it is targeting revenues for the full year to reach $4.826 billion to $4.876 billion, or an implied growth of 34 to 35 percent year-on-year.
However, it expects to book consolidated net loss of $1.099 billion to $1.129 billion.
Bookings are pegged at $6.566 billion to $6.616 billion, or a year-on-year growth of 50 to 51 percent.
For the fourth quarter alone, Roblox Corporation (NYSE:RBLX) is gunning for revenues of $1.35 billion to $1.4 billion, or a year-on-year growth of 37 to 42 percent. Net loss is also projected at $345 million to $375 million.
3. Moderna Inc. (NASDAQ:MRNA)
Moderna rebounded by 17.02 percent on Tuesday to finish at $39.60 apiece as investors took heart from the preliminary results of its earnings performance in full-year 2025.
At the 44th Annual JP Morgan Healthcare Conference on Monday, Moderna Inc. (NASDAQ:MRNA) said that it expects to report revenues of $1.9 billion for full-year 2025, or $100 million over the midpoint of its $1.6 billion to $2 billion guidance range communicated during its third quarter earnings call.
For 2026, Moderna Inc. (NASDAQ:MRNA) reaffirmed plans to deliver up to 10 percent growth and further lower its operating expenses to $4.2 billion to $4.6 billion in a bid to break even in 2028.
“In 2025, we strengthened our commercial execution, successfully launched our third product, and continued to advance our mRNA pipeline. At the same time, we reduced our annual operating expenses by approximately $2 billion, significantly exceeding the financial cost reduction commitments we set at the start of the year,” said Moderna Inc. (NASDAQ:MRNA) CEO Stephane Bancel.
“We remain focused on our strategy to build a large seasonal vaccine franchise for at-risk populations, creating a strong cash engine to fund our next phase of innovation in oncology and rare disease. We expect this approach to support up to 10 percent revenue growth in 2026, as we further reduce costs, expand our commercial portfolio with approvals of additional seasonal vaccines, and anticipate multiple clinical data catalysts driven by our late-stage oncology pipeline.”
Official results are set to be released in the second week of next month.
2. TTM Technologies, Inc. (NASDAQ:TTMI)
TTM Technologies rallied to a new all-time high on Tuesday, as investors snapped up shares after the company earned a 33 percent price target upgrade from an investment firm.
At intra-day trading, the stock jumped to its highest price of $96.45 before trimming gains to end the day just up by 19.71 percent at $93.24 apiece, after Needham & Company significantly raised its price target to $105 from $79 previously. Even with the recent surge, the new figure still marked a 12.6 percent upside from its latest closing price.
Needham also maintained its “buy” recommendation for its stock.
The upgrade followed the participation of TTM Technologies, Inc. (NASDAQ:TTMI) President and CEO Edwin Roks and Chief Finance Officer Dan Boehle at the ongoing Needham Growth Conference on January 13th and 14th at the Lotte New York Palace Hotel in New York.
TTM Technologies, Inc. (NASDAQ:TTMI) is engaged in the production of technology products, including mission systems, radio frequency components, RF microwave/microelectronic assemblies, and technologically advanced printed circuit boards.
For the fourth quarter of 2025, the company targets to register net sales between $730 million and $770 million, as well as diluted earnings per share of $0.60 to $0.70.
1. Erasca Inc. (NASDAQ:ERAS)
Erasca soared to an over three-year high on Tuesday, as investors took heart from an investment firm’s 83 percent price target upgrade for its stock.
At intra-day trading, Erasca Inc. (NASDAQ:ERAS) jumped to its highest price of $7.56 before paring gains to finish the day just up by 20.47 percent at $7.51 apiece.
The rally followed HC Wainwright’s raising of its price target for the company to $11 from $6 previously, while reaffirming its “buy” recommendation.
The upgrade followed Erasca Inc.’s (NASDAQ:ERAS) presentation of preliminary clinical data at the 44th Annual JP Morgan Healthcare Conference on Tuesday, saying that it saw two confirmed partial responses and one unconfirmed partial response during the clinical study of its pan-RAS molecular glue degrader ERAS-0015.
In addition, more unconfirmed responses were observed in patients taking 8 mg doses, with consistent, linear pharmacokinetics across all dose levels evaluated and no evidence of exposure plateau so far.
The topline results are scheduled to be released in the first half of 2026.
While we acknowledge the potential of ERAS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ERAS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
